185039-89-8 | Pd0166285

Packsize	Purity	Availability	Price	Discounted Price
1mg	98%	in stock	$12.00	$8.00
5mg	98%	in stock	$33.00	$23.00
10mg	98%	in stock	$55.00	$38.00
25mg	98%	in stock	$110.00	$77.00
50mg	98%	in stock	$186.00	$130.00
100mg	98%	in stock	$316.00	$221.00

Description

• Catalog Number: AE97201
• Chemical Name: Pd0166285
• CAS Number: 185039-89-8
• Molecular Formula: C26H27Cl2N5O2
• Molecular Weight: 512.4308799999999
• MDL Number: MFCD00950060
• SMILES: CCN(CCOc1ccc(cc1)Nc1ncc2c(n1)n(C)c(=O)c(c2)c1c(Cl)cccc1Cl)CC

Computed Properties

• Complexity: 719
• Covalently-Bonded Unit Count: 1
• Heavy Atom Count: 35
• Hydrogen Bond Acceptor Count: 6
• Hydrogen Bond Donor Count: 1
• Rotatable Bond Count: 9
• XLogP3: 5.6

Literature

• Identification of potent Yes1 kinase inhibitors using a library screening approach.

  Bioorganic & medicinal chemistry letters 20130801

• In vitro and in silico studies on substrate recognition and acceptance of human PKMYT1, a Cdk1 inhibitory kinase.

  Bioorganic & medicinal chemistry letters 20120115

• WEE1 inhibition sensitizes osteosarcoma to radiotherapy.

  BMC cancer 20110101

• 2D Autocorrelation, CoMFA, and CoMSIA modeling of protein tyrosine kinases' inhibition by substituted pyrido[2,3-d]pyrimidine derivatives.

  Bioorganic & medicinal chemistry 20080115

• Cell cycle regulation by the Wee1 inhibitor PD0166285, pyrido [2,3-d] pyimidine, in the B16 mouse melanoma cell line.

  BMC cancer 20060101

• Structure-activity relationships for 2-anilino-6-phenylpyrido[2,3-d]pyrimidin-7(8H)-ones as inhibitors of the cellular checkpoint kinase Wee1.

  Bioorganic & medicinal chemistry letters 20050401

• Wild-type TP53 inhibits G(2)-phase checkpoint abrogation and radiosensitization induced by PD0166285, a WEE1 kinase inhibitor.

  Radiation research 20020301

• Radiosensitization of p53 mutant cells by PD0166285, a novel G(2) checkpoint abrogator.

  Cancer research 20011115

• 2-Substituted aminopyrido[2,3-d]pyrimidin-7(8H)-ones. structure-activity relationships against selected tyrosine kinases and in vitro and in vivo anticancer activity.

  Journal of medicinal chemistry 19980813

• Development of a binding model to protein tyrosine kinases for substituted pyrido[2,3-d]pyrimidine inhibitors.

  Journal of medicinal chemistry 19980521

• In vitro pharmacological characterization of PD 166285, a new nanomolar potent and broadly active protein tyrosine kinase inhibitor.

  The Journal of pharmacology and experimental therapeutics 19971201